Literature DB >> 14587288

Cytokine synergy, collagenases and cartilage collagen breakdown.

Tim E Cawston1, Jenny M Milner, Jon B Catterall, Andrew D Rowan.   

Abstract

We have investigated proteinases that degrade cartilage collagen. We show that pro-inflammatory cytokines act synergistically with oncastatin M to promote cartilage collagen resorption by the up-regulation and activation of matrix metalloproteinases (MMPs). The precise mechanisms are not known, but involve the up-regulation of c-fos, which binds to MMP promoters at a proximal activator protein-1 (AP-1) site. This markedly up-regulates transcription and leads to higher levels of active MMP proteins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14587288     DOI: 10.1042/bss0700125

Source DB:  PubMed          Journal:  Biochem Soc Symp        ISSN: 0067-8694


  4 in total

1.  A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A.

Authors:  Ronan Hugh Mullan; Jennifer McCormick; Mary Connolly; Barry Bresnihan; Douglas James Veale; Ursula Fearon
Journal:  Am J Pathol       Date:  2010-03-19       Impact factor: 4.307

2.  Promotion of the articular cartilage proteoglycan degradation by T-2 toxin and selenium protective effect.

Authors:  Si-Yuan Li; Jun-Ling Cao; Zhong-Li Shi; Jing-Hong Chen; Zeng-Tie Zhang; Clare E Hughes; Bruce Caterson
Journal:  J Zhejiang Univ Sci B       Date:  2008-01       Impact factor: 3.066

3.  Biosynthesis of promatrix metalloproteinase-9/chondroitin sulphate proteoglycan heteromer involves a Rottlerin-sensitive pathway.

Authors:  Nabin Malla; Eli Berg; Ugo Moens; Lars Uhlin-Hansen; Jan-Olof Winberg
Journal:  PLoS One       Date:  2011-06-01       Impact factor: 3.240

4.  Ex vivo model exhibits protective effects of sesamin against destruction of cartilage induced with a combination of tumor necrosis factor-alpha and oncostatin M.

Authors:  Manatsanan Khansai; Kanchanit Boonmaleerat; Peraphan Pothacharoen; Thanyaluck Phitak; Prachya Kongtawelert
Journal:  BMC Complement Altern Med       Date:  2016-07-11       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.